IPO - Medicus Pharma Ltd.

Form Type: 8-K

Filing Date: 2025-06-02

Corporate Action: Ipo

Type: New

Accession Number: 000106299325010687

Filing Summary: On June 2, 2025, Medicus Pharma Ltd. completed a public offering of 2,260,000 units, each unit consisting of one common share and one warrant to purchase one common share at a price of $3.10 per unit. The aggregate gross proceeds from the offering totaled $7,006,000 before placement agent fees and expenses. The proceeds will be utilized primarily to fund a Phase 2 clinical trial for basal cell carcinoma treatment, as well as potential expansions into other trial areas and general corporate purposes. The company entered a Placement Agency Agreement with Maxim Group LLC on May 29, 2025, with customary terms, including a 7.5% cash fee to placement agents for the total raised. Additionally, on June 2, 2025, a Warrant Agency Agreement was established with Odyssey Transfer and Trust Company for the warrants issued in the offering. Moreover, the company executed a securities purchase agreement on May 2, 2025, with YA II PN, Ltd., leading to the issuance of debentures totaling $2,500,000 as of June 2, 2025. A press release announcing the pricing and closing of the offering was issued on May 29, 2025, and June 2, 2025, respectively.

Form Type: 424B4

Filing Date: 2025-05-30

Corporate Action: Ipo

Type: New

Accession Number: 000106299325010548

Filing Summary: Medicus Pharma Ltd. is offering 2,260,000 Units, each consisting of one common share and one warrant at a public offering price of $3.10 per unit, aiming for gross proceeds of approximately $7.0 million. The offering includes warrants that are immediately exercisable for common shares at the same price and will expire five years from issuance. The common shares and Public Warrants are listed on Nasdaq under symbols "MDCX" and "MDCXW", with a fixed price offering expected to close shortly after sales commence. The company may use proceeds freely, without a minimum offering requirement. Risks associated with the offering include the possibility of raising insufficient proceeds to fund business needs. Medicus is also in the process of negotiating the acquisition of Antev Ltd., a UK-based drug development company. This acquisition is expected to close by the end of June 2025, subjected to due diligence and regulatory approvals. Recent developments indicate an increase in patient enrollment for ongoing clinical studies and the initiation of a new clinical study for basal cell carcinoma treatment with approval from the UAE authorities. Additionally, the company has engaged with Yorkville for financing through debentures with a total option of $5 million. Medicus Pharma Ltd. is an emerging growth company and may benefit from reduced reporting requirements as it navigates its IPO and future operations.

Form Type: S-1

Filing Date: 2025-05-27

Corporate Action: Ipo

Type: New

Accession Number: 000106299325010394

Filing Summary: Medicus Pharma Ltd. is filing a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of its securities. The company aims to raise up to approximately $10 million through the offering of 1,375,000 units, each unit consisting of one common share and one warrant to purchase one common share, with an assumed public offering price of $7.29 per unit. The offering has been structured with the involvement of Maxim Group LLC as the exclusive placement agent, who will act on a best efforts basis without a minimum offering requirement. The proceeds from this offering are not being held in an escrow account and will be available to the company immediately. The company is classified as both an emerging growth company and a smaller reporting company, which allows it to benefit from reduced public company disclosure obligations. Medicus Pharma is focused on the clinical development of its product, SkinJect™, which is currently being developed for the treatment of basal cell carcinoma, and aims to conduct further trials on additional skin cancer forms pending available capital.

Form Type: POS AM

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: Update

Accession Number: 000106299325007073

Filing Summary: On April 4, 2025, Medicus Pharma Ltd. filed a post-effective amendment (Form POS AM) for its Form F-1 Registration Statement originally declared effective on November 13, 2024. The amendment officially converts the prior registration statement into a Form S-1, reflecting Medicus's change from a foreign private issuer to a U.S. domestic registrant effective January 1, 2025. This registration impacts the securities to be sold in public offerings, particularly concerning the issuance of 1,115,500 common shares via public warrants at an exercise price of $4.64, expiring on November 15, 2029. The filing includes updates based on the Annual Report on Form 10-K for the year ending December 31, 2024, filed March 28, 2025. The document indicates Medicus's status as an emerging growth company, committing to meeting regulatory requirements and addressing operational risks associated with its clinical development for its product aimed at treating basal cell carcinoma. The company previously announced a voluntary delisting from the TSX Venture Exchange on February 21, 2025, and now trades solely on the Nasdaq.

Form Type: 253G1

Filing Date: 2025-03-07

Corporate Action: Ipo

Type: New

Accession Number: 000106299325004966

Filing Summary: Medicus Pharma Ltd. is conducting an initial public offering (IPO) of 1,490,000 Units, each consisting of one common share and one warrant to purchase one common share, at a price of $2.80 per Unit. The offering, under Tier 2 of Regulation A, is set to commence soon after SEC qualification and will continue until the maximum offering is sold or one year passes. The common shares and public warrants are already listed on Nasdaq under the symbols 'MDCX' and 'MDCXW'. The recent closing prices of these shares on March 6, 2025, were $3.01 and $0.91 respectively. The proceeds from the offering are intended to fund clinical trials for a novel product, SkinJectTM, aimed at treating basal cell carcinoma, and potentially other skin cancers. The offering is being conducted on a 'best-efforts' basis, meaning there is no guaranteed minimum number of Units that must be sold, thereby posing risks to investors regarding their investments. The document also outlines corporate risks, regulatory factors, and the context of Medicus being an emerging growth and smaller reporting company.

Form Type: CORRESP

Filing Date: 2025-03-06

Corporate Action: Ipo

Type: New

Accession Number: 000106299325004733

Filing Summary: Medicus Pharma Ltd. has submitted a request for the qualification date of their Offering Statement on Form 1-A to be accelerated to March 6, 2025, at 5:00 PM ET. This Offering Statement is related to the offering of up to 2,222,222 units, each made up of one common share and one warrant to purchase an additional common share. The document is addressed to the SEC and includes contact information for their special counsel, indicating a formal advancement in their initial public offering process.